As a sports and news photojournalist for a Buffalo television station, J.T. Messinger is used to seeing the world through a camera lens.
“Roswell Park is at the forefront of research on gastroesophageal cancer, and these studies are aiming to improve the efficacy of chemotherapy, immunotherapy and radiation in patients.”
The groundbreaking lung cancer immunotherapy drug CIMAvax-EGF is now being studied in the prevention of the disease.
Because Roswell Park conducted some of the first clinical trials for the drug, patients here have had early access to this novel targeted anticancer therapy.
Chuck Schliecher has hepatitis C to thank for being a liver cancer survivor.
“I can’t even begin to tell you how grateful I am to Dr. Mukherjee, Jody and the entire team at Roswell Park. From the first moment I walked through the doors into the lobby and up to the first floor GI office at Roswell Park, I knew I was in the right place.”
Lymphoma is broadly a cancer of the lymphatic system, an important part of the body’s immune defense against infection and disease
“I was given a choice to see a doctor at another facility, but because of what I know about my wife’s work and the cutting- edge research and treatment at Roswell Park, of course I went to Roswell Park.”
“The immune system is a powerful tool, and only in the last decade have we really begun to tap into its potential as a cancer-fighting powerhouse,” Dr. Puzanov says.
“Cancer patients have to be warriors all the time, but I don’t consider myself one. I had a lot of help from everyone at Roswell — the positivity from everyone at the front desk, the nurses and everyone I met."
“Other than a shot once a month, I’m in no pain,“ Judi says. “Instead, I’ve already lived three years longer than I thought I would at the beginning of this diagnosis. I’m happy to be alive and feeling well, and one day, I hope to ring that Victory Bell at Roswell Park.”
Dr. Wang and her Roswell Park colleagues travel the world to identify new clinical trials for leukemia for our patients at Roswell Park. "Our patients should have access to the same trials as patients in Boston, New York, Chicago and San Francisco."